AZD1775 continued access study to assess safety and tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Study identifier:D6014C00007

ClinicalTrials.gov identifier:NCT03313557

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Medical condition

Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

Wee-1 kinase inhibitor AZD1775

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 27 Oct 2017
Primary Completion Date: 17 May 2019
Study Completion Date: 17 May 2019

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Quintiles, Inc.

Inclusion and exclusion criteria